News
IDIBELL participates in the European Project Evomet, coordinated by IRB Barcelona, which will train future leaders in metastasis research
The goal is to train 15 young researchers in the understanding of metastatic processes and their evolution, with the aim to identify therapeutic solutions. The Evomet consortium is formed by 13 institutions, which include several of the best academic, clinical and industrial centres working in cancer research and metastasis research in Europe. Awarded in the […]
The use of water pipes and passive exposure to their smoke are as harmful as conventional tobacco
Smoking in water pipes and passive exposure to the smoke they produce, increase the risk of lung cancer and other cardiovascular diseases. It is for this reason that its use should be regulated and compliance with the regulations guaranteed.
Artificial intelligence, a new tool against leukemia
Dr. Carolina M. Florian project has been selected by La Caixa Health Research grants
IDIBELL scientists fins a new combination of drugs to treat rhabdomyosarcoma, a highly aggressive tumor in children
The chemoresistance group of IDIBELL and ICO’s ProCURE Program, led by Alberto Villanueva, has transferred its experience in generating orthotopic mouse models in adult patients to the pediatric field.
Sleep eight hours benefit the retention of weaker memories
People who sleep fewer hours show less consistency in the neural patterns of the repetitions, showing less memory retention.
Age and male sex, key factors in the risk of mortality after hospital admission due to COVID-19
A study with the participation of IDIBELL adds complete information on the complications and prognosis of the first 4,035 patients with COVID-19 in the country.
A study determines the prevalence of mutations in two polymerases in patients with hereditary cancer
A team from the IDIBELL-ICO Hereditary Cancer group has studied more than 2,800 patients with a possible hereditary cancer to determine the frequency of pathogenic mutations in the corrective region of two polymerases.
Identifying these mutations can facilitate the early diagnosis and the personalized treatment of these patients.
IDIBELL scientists find a compound that extends life span in mice
Regenerative medicine scientists at IDIBELL in collaboration with partners at Ulm University (Germany) have demonstrated that inhibition of Cdc42 with CASIN can pharmacologically extend lifespan.
Anna Veiga, new IDIBELL Ombudsperson
The appointment coincides with the constitution of the Research Integrity Committee (CIR), chaired by the Ombudsperson and including different members of the IDIBELL research community, and the update of the “Guide to Good Practices in Research in Health Sciences”.